Effect of New High Ankle Block on Wound Healing After the Operation of Debridement of Diabetes Foot
Launched by XUZHOU CENTRAL HOSPITAL · May 1, 2024
Trial Information
Current as of August 19, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
Inclusion criteria: refer to the 2019 World Guide for the Prevention and Treatment of diabetes Feet (DF), DF patients who meet the diagnostic criteria were Wagner\'s grade 2-4, good communication skills and ability to co-operate in completing various monitoring operations. Exclusion criteria: Skin infection at the puncture site; Concomitant severe cardiovascular and cerebrovascular diseases; Significant abnormalities in coagulation function; Mental abnormalities; Dementia and cognitive impairment. Patients were divided into a high ankle block group (HAB) and a general anesthesia group (...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • refer to the 2019 World Guide for the Prevention and Treatment of diabetes Feet (DF), DF patients who meet the diagnostic criteria were Wagner's grade 2-4, good communication skills and ability to co-operate in completing various monitoring operations.
- Exclusion Criteria:
- • Skin infection at the puncture site; Concomitant severe cardiovascular and cerebrovascular diseases; Significant abnormalities in coagulation function; Mental abnormalities; Dementia and cognitive impairment.
About Xuzhou Central Hospital
Xuzhou Central Hospital is a leading medical institution located in Xuzhou, China, renowned for its commitment to advancing healthcare through innovative research and clinical excellence. As a comprehensive teaching hospital, it is equipped with state-of-the-art facilities and a multidisciplinary team of specialists dedicated to providing high-quality patient care and conducting clinical trials. The hospital actively engages in research initiatives aimed at enhancing treatment modalities and improving patient outcomes, positioning itself as a pivotal contributor to the medical community both nationally and internationally. With a focus on ethical practices and patient safety, Xuzhou Central Hospital strives to foster advancements in medical knowledge and therapeutic interventions through rigorous clinical investigation.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Xuzhou, Jiangsu, China
Patients applied
Trial Officials
Kai Wang, MD
Principal Investigator
Xuzhou Central Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported